Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity (2023 - 2026)

Camp4 Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $105.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 68.0% year-over-year to $105.5 million; the TTM figure through Mar 2026 stood at $360.9 million (up 122.19% YoY), while the FY2025 annual figure was $117.8 million, up 50.44% from the prior year.
• Liabilities and Shareholders Equity came in at $105.5 million for Q1 2026 at Camp4 Therapeutics, down from $117.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $117.8 million in Q4 2025 to a low of $21.4 million in Q3 2024.
• A 4-year average of $72.3 million and a median of $70.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 42.52% in 2024 and surged 304.4% in 2025, its largest moves.
• Camp4 Therapeutics' Liabilities and Shareholders Equity stood at $54.9 million in 2023, then surged by 42.52% to $78.3 million in 2024, then soared by 50.44% to $117.8 million in 2025, then decreased by 10.48% to $105.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $105.5 million, $117.8 million, and $86.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison